Key result
Single-session dual-target MRgFUS of STN and VIM appears feasible and safe for Parkinson's disease.
Why the study?
Is dual-target MRgFUS of the STN and VIM nuclei feasible and safe for Parkinson's disease?
Case Report (n=1)
Is dual-target MRgFUS of the STN and VIM nuclei feasible and safe for Parkinson's disease?
This report provides the first documented evidence that combined STN and VIM ablation within a single MRgFUS session is technically feasible for Parkinson's disease.
May streamline single-session dual-target therapy in PD; hypothesis-generating but should not yet change practice.
This report illustrates the technical feasibility and safety of dual-target MRgFUS for Parkinson's disease, achieved through intraoperative, symptom-guided decision-making. To the authors' knowledge, this represents the first documented case of combined STN and VIM ablation within a single MRgFUS session, highlighting a potential framework for adaptive, multitarget lesioning in functional neurosurgery. https://thejns.org/doi/10.3171/CASE2643.
No takes yet. Share an insight, caveat, or question.
Rivera et al. (2026) conducted a case report in Parkinson's disease (n=1). Dual-target magnetic resonance-guided focused ultrasound (MRgFUS) of the STN and VIM was evaluated on Technical feasibility and safety. Dual-target MRgFUS of the STN and VIM within a single session was technically feasible and safe for treating Parkinson's disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: